It is the same molecule as Victoza, which is approved for type 2 diabetes at lower doses.1,2
What it is
Liraglutide is a GLP-1 receptor agonist, an older relative of semaglutide from the same maker. The label explains why a modified molecule is needed: the body's own GLP-1 has a half-life of only 1.5 to 2 minutes because enzymes break it down. Liraglutide is 97% similar to human GLP-1, carries a 16-carbon fatty acid on a spacer, and resists those enzymes, which stretches its half-life to about 13 hours.1 That is long enough for one shot a day, but not one a week as with semaglutide.
How the dose climbs
Saxenda is injected once a day under the skin. The dose rises every week: 0.6 mg in week 1, then 1.2 mg, 1.8 mg, 2.4 mg and, from week 5, 3 mg. For adults 3 mg is the only treatment dose; the lower ones are for the climb. If 3 mg cannot be tolerated, the label says to stop Saxenda, and if a step causes trouble the climb can be delayed by about a week.1
The label also sets a test that the newer weekly medicines do not have. Sixteen weeks after starting, weight is checked, and if an adult has not lost at least 4% of starting weight, Saxenda is to be stopped, since clinically meaningful weight loss is then unlikely with more treatment.1
What it did in trials
Three 56-week trials support the weight approval in adults.1
- Without diabetes. 3,731 adults who started at an average of 106.2 kg lost 7.4% on Saxenda against 3.0% on placebo. At least 5% was lost by 62.3% against 34.4%, and more than 10% by 33.9% against 15.4%.
- With type 2 diabetes. Weight fell by 5.4% against 1.7%.
- After a diet. In adults who had already lost at least 5% by dieting, Saxenda took off another 4.9%, while weight on placebo rose by 0.3%.
The weekly medicines that followed lower weight further in their own trials: 14.9% on Wegovy 2.4 mg over 68 weeks, for example.3 The trials were run separately and are not a direct comparison. Our Wegovy weight loss chart shows how the Wegovy curve builds week by week.
Side effects and warnings
In the label's trials, nausea was reported by 39.3% on Saxenda against 13.8% on placebo, diarrhea by 20.9% against 9.9%, constipation by 19.4% against 8.5% and vomiting by 15.7% against 3.9%. Injection-site reactions were reported by 13.9% against 10.5%.1 Our page on nausea on a GLP-1 covers what helps.
Saxenda carries the boxed warning about thyroid C-cell tumors seen in rats and mice and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. It is not to be combined with another liraglutide product or with any other GLP-1 receptor agonist. Its label dropped the warning on suicidal behavior and ideation in February 2026.1
Saxenda in eight lines
| Fact | Saxenda |
|---|---|
| Active ingredient | Liraglutide |
| Maker | Novo Nordisk |
| First U.S. approval | 2010, as liraglutide |
| How often | Once a day, under the skin |
| Treatment dose | 3 mg, reached in week 5 |
| Half-life | About 13 hours |
| Stop rule | Under 4% lost by week 16 |
| Youngest age | 12, over 60 kg |
SAXENDA prescribing information, DailyMed version of June 15, 2026.1
Related terms
Victoza is liraglutide for type 2 diabetes at up to 1.8 mg a day. Wegovy and Zepbound are the weekly injections approved for the same weight use. Our page on GLP-1 costs without insurance compares self-pay prices.
Sources
- SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published June 15, 2026; boxed warning, recent major changes and sections 1, 2, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
- VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published November 17, 2025; section 1. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov
Related analyses
Wegovy weight loss chart: the trial results week by week, in your own weight
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Zepbound plateau: when weight loss slows, why, and what the trials show
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Log each daily Saxenda dose and your weight, and see week 16 coming.
Open Dose Insider